<< Back to News

System Formulary Update
Lecanemab-irmb (Leqembi)

Situation:

Lecanemab-irmb (Leqembi) was approved for addition to the health system formulary at the August 20203 System Pharmacy and Therapeutics Committee Meeting.

Background:

The following medication was reviewed: Lecanemab-irmb 100 mg/mL intravenous solution , 200 mg/2 mL SDV, and 500 mg/5 mL SDV

Assessment/Recommendations:

System P&T voted to include the following product from the UNC Health Medication Formulary:

• Lecanemab-irmb 100 mg/mL IV solution
• Lecanemab-irmb 200 mg/2 mL SDV
• Lecanemab-irmb 500 mg/5 mL SDV

System P&T has approved the following restrictions to more closely regulate use:

• Restricted to outpatient/clinic encounters only (i.e., no inpatient use)
• A benefits investigation must be completed prior to use
• Cannot be initiated in patients who:
  • Are ApoE4 homozygotes (ApoE4 status must be confirmed prior to initiation)
  • Have had a TIA/CVA in the past 12 months prior to initiation
• Orders must be signed by a neurology attending physician at designated clinics

Note: Stock of this formulary product may vary at individual entities 

Formulary/Epic Changes will Go-Live on Tuesday, October 3, 2023